Hospital Mater Dei (MATD3) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 Jul, 2026Executive summary
Achieved record net revenue of R$575 million in Q1 2026, up 15.1% year-over-year, driven by higher occupancy, improved ticket mix, and operational efficiency despite seasonal headwinds.
Adjusted EBITDA reached R$130 million, up 34.6%–35% year-over-year, with margin expanding 3.3 percentage points to 22.6%.
Net income grew 66.7%–80% year-over-year to R$36.3 million, with a margin of 6.3%.
Record occupancy rate of 84.3%, up 4.6 percentage points year-over-year, and operational beds remained stable.
Fitch and Moody's reaffirmed AA/AA+ ratings, reflecting strong cash generation and financial discipline.
Financial highlights
Net revenue for Q1 2026 was R$575 million, up 15.1% year-over-year.
Average ticket per bed rose 8.4% year-over-year to R$2.86 million.
Adjusted EBITDA margin improved to 22.6%, up 3.3 percentage points year-over-year.
Gross margin was 30.2%, with costs at 69.8% of revenue, down 1.4 percentage points year-over-year.
Adjusted net profit margin reached 6.3% in Q1 2026.
Outlook and guidance
Management projects continued positive cash generation, margin maintenance, and gradual maturation of hospital assets.
Focus remains on deleveraging, disciplined capital allocation, and selective M&A as financial position strengthens.
Plans to open new hospital beds in coming quarters, maintaining occupancy above 80%.
Latest events from Hospital Mater Dei
- Net revenue rose 1.8% to R$2.2bn, but margins fell due to higher costs and a one-off loss.MATD3
Q4 202413 Jul 2026 - Net revenue rose 5.6% YoY, but a BRL 744m impairment drove a net loss in Q2.MATD3
Q2 20248 Jul 2026 - Record revenue, EBITDA, and net income growth, driven by oncology and innovation in 3Q25.MATD3
Q3 20258 Jul 2026 - Record revenue, EBITDA, and net income with strong cash flow and higher dividends in 2025.MATD3
Q4 20256 Jul 2026 - Net profit surged 148% sequentially as margins and cash flow improved, with AA+ rating reaffirmed.MATD3
Q1 20256 Jul 2026 - Record revenue and EBITDA, margin expansion, and lower leverage highlighted the quarter.MATD3
Q2 20256 Jul 2026 - CSN divestment cut net debt 36% as Nova Lima unit expanded capacity and cash rose.MATD3
Q3 20242 Jul 2026